Table 1. Survival rates of adult patients with acute myeloid leukemia following allogeneic hematopoietic cell transplantation by donor type.
| Disease stage at time of hematopoietic cell transplantation*1 | |||
| Donor type*2 | First remission | Second remission | No remission/recurrence |
| HLA-identical sibling | 58% (N = 5 317) | 54% (N = 1 226) | 31% (N = 1 721) |
| HLA-compatible unrelated donor | 56% (N = 7 441) | 54% (N = 1 940) | 31% (N = 2 463) |
| Partially HLA-compatible unrelated donor | 50% (N = 1 314) | 42% (N = 5 077) | 26% (N = 549) |
| Haploidentical related donor | 53% (N = 572) | 55% (N = 1 977) | 28% (N = 706) |
*1 Hematopoietic cell transplants performed between 2009 and 2019 at centers in the USA, predominantly under GvHD prophylaxis with calcineurin inhibitors (4). Data expressed as Kaplan–Meier probabilities of 3-year survival, followed in parentheses by the number of patients in the group. *2 Donor types according to Table 2. GvHD, Graft versus host disease; HLA, human leukocyte antigens